Literature DB >> 20523794

The impact of chronic idiopathic urticaria on quality of life in korean patients.

Min Ju Kang1, Hei Sung Kim, Hyung Ok Kim, Young Min Park.   

Abstract

BACKGROUND: Chronic idiopathic urticaria (CIU) is a relatively common disease, and yet not much is known about the causative factors or its pathophysiology, which makes it difficult to cure. Due to its chronic nature, many patients have significantly reduced quality of life (QOL).
OBJECTIVE: The purpose of this study was to assess the impact of CIU on QOL of Korean patients, and to determine whether a relationship exists between QOL and the severity of disease.
METHODS: One hundred sixty three patients with CIU, who first visited our out-patient clinic between August 2005 and July 2007, were asked to complete two questionnaires: one designed to assess the clinical features of their disease; the other on the influences of CIU on their daily lives. QOL was divided into six categories: mental status (MS), daily living activities (DLA), leisure activities (LA), self-perception (SP), treatment-induced restrictions (TIR), and social functions (SF). All of the QOL scores were recalibrated to a 0~100 scale, with 100 indicating the worst QOL, and 0 the best.
RESULTS: THE AVERAGE QOL SCORES OBTAINED FROM THE QUESTIONNAIRE WERE AS FOLLOWS: SP (13.1+/-4.6), DLA (12.0+/-4.3), MS (10.3+/-3.3), SF (8.5+/-3.4), LA (6.1+/-3.0), and TIR (5.5+/-2.6). SP was the domain that was most affected; TIR the least. There were positive correlations between pairs of the six different QOL categories (p<0.001). These results demonstrate that CIU exerts an influence on many aspects of QOL. TIR was significantly affected in longer term CIU cases (p<0.05), while SP, MS, DLA, SF, and SR scores did not correlate with disease duration. Disease severity was found to have a significant impact on SP, MS, SF, and LA (p<0.05). In patients with concurrent physical urticaria, DLA and SF scores were significantly affected (p<0.05).
CONCLUSION: Based on these results, it is suggested that CIU has a negative impact on QOL in Korean patients. Therefore, it is important to recognize the effects CIU can have on QOL and consider them in evaluating the response to treatment.

Entities:  

Keywords:  Chronic idiopathic urticaria; Quality of life; Questionnaire

Year:  2009        PMID: 20523794      PMCID: PMC2861226          DOI: 10.5021/ad.2009.21.3.226

Source DB:  PubMed          Journal:  Ann Dermatol        ISSN: 1013-9087            Impact factor:   1.444


  9 in total

Review 1.  EAACI/GA2LEN/EDF guideline: definition, classification and diagnosis of urticaria.

Authors:  T Zuberbier; C Bindslev-Jensen; W Canonica; C E H Grattan; M W Greaves; B M Henz; A Kapp; M M A Kozel; M Maurer; H F Merk; T Schäfer; D Simon; G A Vena; B Wedi
Journal:  Allergy       Date:  2006-03       Impact factor: 13.146

2.  The impact of chronic urticaria on the quality of life.

Authors:  B F O'Donnell; F Lawlor; J Simpson; M Morgan; M W Greaves
Journal:  Br J Dermatol       Date:  1997-02       Impact factor: 9.302

3.  Comparative study of the impact of chronic urticaria, psoriasis and atopic dermatitis on the quality of life.

Authors:  J J Grob; J Revuz; J P Ortonne; P Auquier; G Lorette
Journal:  Br J Dermatol       Date:  2005-02       Impact factor: 9.302

4.  Dermatology Life Quality Index (DLQI)--a simple practical measure for routine clinical use.

Authors:  A Y Finlay; G K Khan
Journal:  Clin Exp Dermatol       Date:  1994-05       Impact factor: 3.470

5.  The extent and nature of disability in different urticarial conditions.

Authors:  E Poon; P T Seed; M W Greaves; A Kobza-Black
Journal:  Br J Dermatol       Date:  1999-04       Impact factor: 9.302

6.  Validation of the Dermatology Life Quality Index as an outcome measure for urticaria-related quality of life.

Authors:  Richard D Lennox; Michael J Leahy
Journal:  Ann Allergy Asthma Immunol       Date:  2004-08       Impact factor: 6.347

7.  The levels of depression, anxiety and quality of life in patients with chronic idiopathic urticaria.

Authors:  B Engin; F Uguz; E Yilmaz; M Ozdemir; I Mevlitoglu
Journal:  J Eur Acad Dermatol Venereol       Date:  2008-01       Impact factor: 6.166

8.  Cetirizine and astemizole therapy for chronic idiopathic urticaria: a double-blind, placebo-controlled, comparative trial.

Authors:  D Breneman; E A Bronsky; S Bruce; J T Kalivas; G L Klein; H L Roth; M D Tharp; C Treger; N Soter
Journal:  J Am Acad Dermatol       Date:  1995-08       Impact factor: 11.527

9.  Minimal important difference (MID) of the Dermatology Life Quality Index (DLQI): results from patients with chronic idiopathic urticaria.

Authors:  Richard Shikiar; Gale Harding; Michael Leahy; Richard D Lennox
Journal:  Health Qual Life Outcomes       Date:  2005-05-20       Impact factor: 3.186

  9 in total
  20 in total

Review 1.  Benefits and Harms of Omalizumab Treatment in Adolescent and Adult Patients With Chronic Idiopathic (Spontaneous) Urticaria: A Meta-analysis of "Real-world" Evidence.

Authors:  Michael D Tharp; Jonathan A Bernstein; Abhishek Kavati; Benjamin Ortiz; Karen MacDonald; Kris Denhaerynck; Ivo Abraham; Christopher S Lee
Journal:  JAMA Dermatol       Date:  2019-01-01       Impact factor: 10.282

2.  Economic burden of refractory chronic spontaneous urticaria on Kuwait's health system.

Authors:  Mona Al-Ahmad; Maryam S Alowayesh; Norman V Carroll
Journal:  Clinicoecon Outcomes Res       Date:  2016-05-10

3.  Treatment of Chronic Spontaneous Urticaria with a Single Dose of Omalizumab: A Study of Four Cases.

Authors:  Radhakrishnan Subramaniyan; Ajay Chopra
Journal:  Indian J Dermatol       Date:  2016 Jul-Aug       Impact factor: 1.494

4.  The Impact of Chronic Urticaria from the Patient's Perspective: A Survey in Five European Countries.

Authors:  Maria-Magdalena Balp; Jeffrey Vietri; Haijun Tian; Gina Isherwood
Journal:  Patient       Date:  2015-12       Impact factor: 3.883

Review 5.  The challenges of chronic urticaria part 1: Epidemiology, immunopathogenesis, comorbidities, quality of life, and management.

Authors:  Mario Sánchez-Borges; Ignacio J Ansotegui; Ilaria Baiardini; Jonathan Bernstein; Giorgio Walter Canonica; Motohiro Ebisawa; Maximiliano Gomez; Sandra Nora Gonzalez-Diaz; Bryan Martin; Mário Morais-Almeida; Jose Antonio Ortega Martell
Journal:  World Allergy Organ J       Date:  2021-06-01       Impact factor: 4.084

6.  Diagnosis and treatment of urticaria and angioedema: a worldwide perspective.

Authors:  Mario Sánchez-Borges; Riccardo Asero; Ignacio J Ansotegui; Ilaria Baiardini; Jonathan A Bernstein; G Walter Canonica; Richard Gower; David A Kahn; Allen P Kaplan; Connie Katelaris; Marcus Maurer; Hae Sim Park; Paul Potter; Sarbjit Saini; Paolo Tassinari; Alberto Tedeschi; Young Min Ye; Torsten Zuberbier
Journal:  World Allergy Organ J       Date:  2012-11       Impact factor: 4.084

7.  ASSURE-CSU: a real-world study of burden of disease in patients with symptomatic chronic spontaneous urticaria.

Authors:  Karsten Weller; Marcus Maurer; Clive Grattan; Alla Nakonechna; Mohamed Abuzakouk; Frédéric Bérard; Gordon Sussman; Ana M Giménez-Arnau; Javier Ortiz de Frutos; André Knulst; G Walter Canonica; Kelly Hollis; Doreen McBride; Maria-Magdalena Balp
Journal:  Clin Transl Allergy       Date:  2015-08-17       Impact factor: 5.871

Review 8.  Role of bilastine in the management of allergic rhinitis and urticaria: an Asia-Pacific consensus statement.

Authors:  Ralph Mösges; Dennis Lip Yen Lee; Jovilia Abong; Bella Siasoco; Steven Kw Chow; Jern-Lin Leong; Harvinder Singh; S Kuljit; Benjamin Campomanes
Journal:  Asia Pac Allergy       Date:  2016-01-27

Review 9.  Position statement for the use of omalizumab in the management of chronic spontaneous urticaria in Indian patients.

Authors:  Kiran Godse; Murlidhar Rajagopalan; Mukesh Girdhar; Sanjiv Kandhari; Bela Shah; Prashant N Chhajed; Sushil Tahiliani; D S Krupa Shankar; Vijay Somani; Vijay Zawar
Journal:  Indian Dermatol Online J       Date:  2016 Jan-Feb

10.  Omalizumab substantially improves dermatology-related quality of life in patients with chronic spontaneous urticaria.

Authors:  A Y Finlay; A P Kaplan; L A Beck; E N Antonova; M-M Balp; J Zazzali; S Khalil; M Maurer
Journal:  J Eur Acad Dermatol Venereol       Date:  2017-07-19       Impact factor: 6.166

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.